Arcus Biosciences Inc. Stock News
$15.07
+0.140 (+0.94%)
At Close: May 31, 2024
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Friday, 24'th May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Thursday, 09'th May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
09:55pm, Wednesday, 08'th May 2024
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - CEO Jennifer
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
06:46pm, Wednesday, 08'th May 2024
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $1.09 per share a year ago.
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
04:05pm, Thursday, 02'nd May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
11:05am, Wednesday, 01'st May 2024
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
04:00pm, Wednesday, 24'th Apr 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
04:05pm, Tuesday, 23'rd Apr 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 09'th Apr 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 26'th Mar 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Monday, 11'th Mar 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
04:05pm, Wednesday, 28'th Feb 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 27'th Feb 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet
10:56am, Thursday, 22'nd Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questio
Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript
02:08am, Thursday, 22'nd Feb 2024
Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript
